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Abstract
Statin therapy may represent a potential prophylactic intervention
in certain high-risk scenarios, for example in pandemic influenza
and in those undergoing aggressive medical treatments. Emerging
data indicate a potential prophylactic role in these high-risk groups.
Introduction
Prophylaxis is defined as ‘preventive treatment against
disease’. A prophylactic measure that dampens the systemic
response to infection or physiologic stress and has direct
effects against the trigger of that response could greatly
reduce the burden of illness associated with critical illness.
Numerous clinical trials have provided unequivocal evidence
that statins are safe and effective in preventing cardiovascular
morbidity and mortality, and many statin-associated benefits
are considered to stem from effects other than lipid
modulation [1,2]. Intriguingly, observations indicate that
statins may also directly affect the infectivity and proliferation
of some microorganisms.
Viruses
Statins decrease viral loads and increase CD4+ cell counts in
an in vivo model of acute HIV-1 infection [3]. Changes in Rho-
controlled actin cytoskeleton rearrangements inhibit HIV-1
entry into and exit from host cells. Furthermore, many statins
directly block the interaction between intercellular adhesion
molecule (ICAM)-1 and leukocyte function-associated antigen
(LFA)-1 by binding to a site within LFA-1 [4]. Consequently,
the initial steps in virus replication can be limited. Moreover, six
chronically HIV-1-infected, non-highly active antiretroviral
therapy (HAART)-treated patients with stable viral loads for at
least 6 months received lovastatin as sole therapy for 1 month
[3]. Serum viral RNA loads were reduced in all patients, but
they rebounded after lovastatin was withdrawn.
Statins also inhibit the replication of cytomegalovirus (CMV).
Analysis of human umbilical-vein endothelial cells infected
with CMV and co-incubated with fluvastatin demonstrate
significant reductions in CMV DNA [5]. Viral particle
concentrations are also lower. These effects are seen in
doses consistent with blood concentrations in vivo observed
during therapy in humans [6]. At high concentrations,
lovastatin also strongly reduces hepatitis C virus RNA levels
in cultured hepatoma cells and inhibits respiratory syncytial
virus in vitro and in vivo in mice [7,8].
Bacteria and fungi
Lovastatin inhibits the sterol biosynthetic pathway in host
cells containing Salmonella typhimurium and reduces the
bacterium’s intracellular proliferation in cultured macrophages
[9]. Host cell death is implicated as a possible mechanism.
Importantly, these effects were produced at plasma
concentrations normally achieved during patient treatment. In
the same study, mice were treated for 7 days with
atorvastatin, then rendered septic by intraperitoneal injection
of  S. typhimurium and treated for a further 2 days after
infection. Bacterial numbers in the livers and spleens of
treated mice were reduced by more than 60%.
Ergosterol is the main sterol of fungal plasma membranes.
The fungicidal polyenes and the fungistatic azoles are both
directed against Candida albicans ergosterol. Micromolar
concentrations of fluvastatin are fungicidal for Candida
species [10]. In a recent study lovastatin reduced C. albicans
gene expression, and consequently the organism’s growth, by
inhibiting the sterol pathway [11]. Synergism between
lovastatin (5 µg/ml) and low concentrations of fluconazole
was also observed.
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Potential implications
Although these findings must be confirmed, they raise several
scientific and clinically important questions.
Do statins present a potential preventive and/or
supplementary treatment for seasonal influenza and for
the expected influenza pandemic?
Some viruses, notably H5N1, are highly potent inducers of a
so-called ‘cytokine storm’ [12,13]. This excessive proinflam-
matory response contributes to the pathogenesis of severe
influenza pneumonia and may partly explain the high mortality
rates in young, otherwise healthy adults during the pandemic
of 1918 to 1919 [13,14].
The immunomodulatory effects of statins occur through
several pathways [15-17]. These include the direct activation
of heme oxygenase, interference in leukocyte–endothelium
interaction, and through inhibition of major histocompatability
class II complexes [4,18-20]. The most important, however,
involves intracellular inflammatory signalling. GTP-binding
proteins are crucial for intracellular inflammatory signalling by
acting as molecular on/off switches for various protein
kinases. They cycle between active and inactive states and
must undergo isoprenylation to enable pathway activation. By
inhibiting 3-hydroxy-3-methylglutaryl-CoA reductase, statins
slow, but do not abolish, protein isoprenylation. This
decrease in prenylated protein concentration reduces the
response magnitude of the affected signalling pathways and
may therefore counterbalance the influenza virus-associated
‘cytokine storm’ [15,16].
Considering these effects, the findings that statins also have
direct antiviral effects, in some cases at physiologically
relevant concentrations, raises the possibility that they may
prove a valuable adjuvant therapy in the battle against
seasonal and pandemic influenza, particularly in health
systems unable to pay for expensive antiviral drugs or
vaccines. The expected influenza pandemic represents a
significant challenge to health care systems and to
governments eager to avoid the potential human and
economic consequences of large-scale infection and death.
As things stand, the world is ill-prepared for a pandemic.
Current world vaccine production capacity is only sufficient
for a maximum of 450 million people to be vaccinated, and
clinical trials of H5N1 vaccines have been disappointing [21].
Most of the world’s people will therefore not have access to
these vaccines.
Should patients at high risk of developing severe sepsis
or septic shock receive ‘prophylactic’ statin therapy?
Early animal and human observational data suggest that statins
may prevent sepsis and severe sepsis, and further data hint at
a potential treatment effect [16,17]. Several observational
studies specifically investigated the effects of statins in
populations with infections or bacteremia [17]. Results again
point to a preventive, and potentially a treatment, role.
Data indicate that a high proportion of patients presenting
with systemic inflammatory response syndrome, infection or
sepsis worsen to severe sepsis or septic shock. A recent
study by Alberti and colleagues [22] provides data on the
progression to severe sepsis and septic shock in patients
admitted to ICU with an infection and/or sepsis: 11% of
patients with infection and/or sepsis progressed to severe
sepsis, whereas 13% progressed to septic shock. The overall
crude hospital mortality rate was 41%. Hospital mortality
rates ranged from 17% in those with sepsis without
progression, to 97% in those who developed, and remained
in, septic shock.
Patients who may benefit from prophylaxis are those admitted
to hospital with an infection and who have a high likelihood of
progression, or those placed at high risk by medical
treatment. The latter group may include patients in whom
bacteremia is expected, for example when non-sterile body
cavities are opened (perioperative prophylaxis), or immuno-
compromised patients undergoing chemotherapy and those
who have received solid organ or stem cell transplants
(prevention of infections).
Statin therapy may represent a potential prophylactic
intervention in certain high-risk settings. In view of the well-
documented safety of statins, and the low cost of some
preparations, research is needed to address these questions.
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